Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.17/620
Título: Effects of Sevelamer Hydrochloride and Calcium Carbonate on Renal Osteodystrophy in Hemodialysis Patients
Autor: Ferreira, A
Frazão, JM
Monier-Faugere, MC
Gil, C
Galvão, J
Oliveira, C
Baldaia, J
Rodrigues, I
Santos, C
Ribeiro, S
Hoenger, R
Duggal, A
Malluche, HH
Palavras-chave: Biópsia
Calcificação Fisiológica
Cálcio
Carbonato de Cálcio
Falência Renal Crónica
Hormona Paratiroideia
Diálise Renal
Osteodistrofia Renal
Resultado de Tratamento
Data: 2008
Editora: American Society of Nephrology
Citação: J Am Soc Nephrol. 2008 Feb;19(2):405-12
Resumo: Disturbances in mineral metabolism play a central role in the development of renal bone disease. In a 54-wk, randomized, open-label study, 119 hemodialysis patients were enrolled to compare the effects of sevelamer hydrochloride and calcium carbonate on bone. Biopsy-proven adynamic bone disease was the most frequent bone abnormality at baseline (59%). Serum phosphorus, calcium, and intact parathyroid hormone were well controlled in both groups, although calcium was consistently lower and intact parathyroid hormone higher among patients who were randomly assigned to sevelamer. Compared with baseline values, there were no changes in mineralization lag time or measures of bone turnover (e.g., activation frequency) after 1 yr in either group. Osteoid thickness significantly increased in both groups, but there was no significant difference between them. Bone formation rate per bone surface, however, significantly increased from baseline only in the sevelamer group (P = 0.019). In addition, of those with abnormal microarchitecture at baseline (i.e., trabecular separation), seven of 10 in the sevelamer group normalized after 1 yr compared with zero of three in the calcium group. In summary, sevelamer resulted in no statistically significant changes in bone turnover or mineralization compared with calcium carbonate, but bone formation increased and trabecular architecture improved with sevelamer. Further studies are required to assess whether these changes affect clinical outcomes, such as rates of fracture.
Peer review: yes
URI: http://hdl.handle.net/10400.17/620
Aparece nas colecções:NEF - Artigos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
J Amer Soc Nephrol 2008 405.pdf164,09 kBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.